Actuate Therapeutics opened higher at $0.33, compared with its previous close of $0.30. In the last trading session, the stock traded between $0.29 and $0.35. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Actuate Therapeutics is now worth
$ 3.44
Resulting in a loss of
$ 96.56 (96.56%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.01 (-2.05%)
Day High
$0.35
Day Low
$0.29
Day Open
$0.33
Prev Close
$0.30
Volume
1,54,228
1W Return
-20.43%
1M Return
-53.89%
3M Return
-70.98%
6M Return
-90.05%
1Y Return
-95.22%
Fundamentals
Market Cap ($ Mn)
16
PE Ratio
-
PB Ratio
40.18
PEG Ratio
-
ROE
-990.28%
ROCE
-846.74%
EPS (TTM)
-
Investment Returns
1 Week
-20.43%
1 Month
-53.89%
3 Months
-70.98%
6 Months
-90.05%
9 Months
-92.99%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
7Oct
Actuate Therapeutics to sell 50 million shares at assumed $0.819 price
Actuate Therapeutics plans to sell 50,000,000 shares. Assumed offering price is $0.819 per share. Details disclosed in recent SEC filing.
1mo ago
24Jun
Actuate wins 2026 Colorado Companies to Watch award
Actuate, a Colorado-based cleantech company, has been named a 2026 Colorado Companies to Watch winner for its predictive building intelligence platform serving small and mid-sized commercial buildings. The award recognizes the firm for targeting the roughly 80% of commercial buildings without building management systems. Clients report 10–30% lower energy costs, 20–30% lower maintenance costs, 40–60% fewer emergency service calls, and 50% less downtime. In 2026, Actuate is scaling sales and incorporating agentic AI into its platform.
4mo ago
9Jun
Actuate's elraglusib to be evaluated in BEACON2 pediatric trial
Actuate Therapeutics announced that elraglusib will be evaluated in the BEACON2 clinical trial for children with relapsed and refractory neuroblastoma. The trial will assess the drug in combination with dinutuximab beta and chemotherapy, starting with a dose confirmation cohort of up to 20 patients to determine safety, MTD, RP2D, and PK profile. A randomized portion with approximately 75 patients and a planned interim analysis may follow.
